Although the drugs target different molecular pathways, he said, the pathways they use to bolster T-cell antitumor activity against these deadly cancers are closely related. Ipilimumab, often referred to simply as "ipi," blocks the cytotoxic T-lymphocyte antigen 4 (CTLA-4) protein, which slows T-cell activation. Nivolumab interacts directly with cancer cells, blocking the interaction between the programmed death 1 (PD-1) protein on T cells and PD-L1, a ligand that binds to PD-1 and sits on the surface of some cancer cells when they're under attack.
At the National Comprehensive Cancer Network's 19th annual conference in Hollywood, Fla., themed "Advancing the Standard of Cancer Care," Thompson addressed new agents and opportunities for treating melanoma while offering a guideline update (he serves on the organization's clinical guidelines committee). With the changing landscape for treating these latestage cancers, he said afterward, revising guidelines can be challenging. But the committee reviews them often, he said, adding new treatment options whenever possible.
One example where reviewers moved quickly to place a new therapy on the "preferred list," Thompson said, occurred earlier this year. The U.S. Food and Drug Administration granted accelerated approval to the first molecularly targeted combination for inoperable, metastatic melanoma in patients carrying a genetic mutation, known as BRAF. BRAF-mutated melanoma occurs in roughly 38% of patients, Thompson said, although "a large part of the molecular pie is still unknown."
The combination therapy, targeting both the BRAF mutation and MEK further downstream (N. Engl. J. Med. 2012; 367:1694-703) , had positive results, Thompson said. Patients had a least 9.5 months of progression-free survival while circumventing the resistance common with a single agent. Moreover, despite common side effects of chills and fever, sometimes requiring patients to stop therapy, he said, far fewer secondary skin JNCI | News 5 of 9 jnci.oxfordjournals.org N E W S cancers occurred in patients on the dual treatments. Surprisingly, perhaps, older patients often carry a different type of BRAF mutation from that seen in younger patients, for
reasons not yet clearly understood.
"But this doesn't mean you don't use a BRAF-targeted therapy-just that the duration of response may be less," Thompson said. "It's important for treating doctors to understand this."
Immunotherapy Plus Targeted Therapy?
As scientists unravel the molecular drivers of melanoma and develop monoclonal antibodies that disarm the immune system's checkpoint inhibitors, interest in combining these approaches has grown. Early attempts, however, didn't go well, Thompson conceded, notably an attempt to combine vemurafenib, which targets the BRAF mutation, with ipilimumab. Patients in the first phase I study experienced unexpected toxic effects on the liver (N. Engl. J. Med. 2013; 368:1365-6) , so investigators shut the trial down. Nevertheless, interest is still there, Thompson said.
"Instead of giving these drugs at the same time, it might be better to give one first, then the other," adding that "we could be surprised at the outcome." Some data suggest that targeted drugs enhance the immune response at the tumor site, Thompson said, preparing for followup with immunotherapy.
Investigators also are looking to combine immune-checkpoint inhibitors, such as anti-PD-1s, with adoptive T-cell therapy, an approach that the National Cancer For describing any of these strategies, however-including immune-checkpoint inhibitors-he considers the term breakthrough a bad word, he said.
"But are they an advance? Absolutely." Compared with chemotherapy, where you might see a response rate of 10%-20%, Weber said, response rates with immune-checkpoint inhibitors are 30% or better and last much longer-sometimes 2 years.
For cancers such as melanoma, where advanced stages often carry a grim prognosis, Weber added, "that's pretty good."
The American Cancer Society estimates that doctors will diagnose 76,100 melanoma cases in 2014 and that 9,710 men and women will die of their disease. Five-year survival for stage IV melanoma is 15%-20%, compared with 92%-97% with early detection.
Awaiting Approval
Nivolumab is one of two new immunecheckpoint inhibitors poised for FDA approval by the end of the year, according to Weber. His research group found, in a six-cohort study involving 90 late-stage melanoma patients, that the drug is well tolerated and works either in combination with ipilimumab or sequentially after treatment with ipilimumab alone fails. The Journal of Clinical Oncology published the study were published last October (J. Clin. Oncol. 2013; 31:4311-8 In the community, physicians such as Terrence Cronin Jr., M.D., past president of the Florida Society of Dermatologic Surgeons, see melanoma far too often, especially in a state where residents face constant UV radiation.
Fortunately, he said, most patients in his Melbourne practice are diagnosed with melanoma in situ, caught early and easily treatable. So even though the diagnosis is bad news, Cronin said, "it makes us wants to dance; the prognosis is excellent."
Cronin monitors research developments. He said he considers progress on the molecular front quite hopeful, especially in the last few years, as scientists find checkpoints that prevent T cells from doing their job and identify molecular pathways that enable melanoma to grow.
"Eventually, I think we're going to find melanoma is not all one disease, but different diseases with different patterns and different risks," he said. 
